Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine

References

• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: (2nd Edition). Cephalalgia24(Suppl. 1), 9–160 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine. Lancet363, 381–391 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache45(Suppl. 1), S3–S13 (2005).
   Google Scholar
• Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J. Headache Pain6, 429–440 (2005).
   PubMedGoogle Scholar
• Dahlöf C. Assessment of health-related quality of life in migraine. Headache13, 233–237 (1993).
   Google Scholar
• Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache33, 29–35 (1993).
   PubMed Web of Science ®Google Scholar
• Cerbo R, Pesare M, Aurilia C, Rondelli V, Barbanti P. Socio-economic costs of migraine. J. Headache Pain2, S15–S19 (2001).
   Google Scholar
• Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache42, 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Rothrock JF. The price of pain. Headache46(6), 1011 (2006).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication – a review. Cephalalgia24, 321–332 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol.47, 614–624 (2000).
   PubMed Web of Science ®Google Scholar
• Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine. CNS Drugs18(6), 337–342 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol.55(1), 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs55, 889–922 (1998).
   PubMed Web of Science ®Google Scholar
• Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache41, 862–866 (2001).
   PubMed Web of Science ®Google Scholar
• Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia17, 31–36 (1998).
   Web of Science ®Google Scholar
• Dahlöf CG, Saiers J. Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineurs. Headache38, 756–763 (1998).
   PubMed Web of Science ®Google Scholar
• Dahlöf C. Integrating the triptans into clinical practice. Curr. Opin. Neurol.15(3), 317–322 (2002).
   PubMed Web of Science ®Google Scholar
• Walls C, Lewis A, Bullman J et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr. Med. Res. Opin.20, 803–809 (2004).
   PubMed Web of Science ®Google Scholar
• Moen MD, Keating GM. Sumatriptan fast-disintegrating/rapid-release tablets. Drugs66(6), 883–890 (2006).
   PubMed Web of Science ®Google Scholar
• Dahlöf C. Update on sumatriptan: new progress in migraine treatment. Therapy2(3), 349–356 (2005).
   Google Scholar
• Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can. J. Neurol. Sci.26(3), S12–S19 (1999).
   PubMed Web of Science ®Google Scholar
• Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs63(21), 2285–305 (2003).
   PubMed Web of Science ®Google Scholar
• Kori SH, Sandefer EP, McDonald SA et al. Improved disintegration and gastric emptying of sumatriptan tablets formulated with RT Technology™. Neurology64(6 Suppl. 1), A349 (2005) (Abstract P06.031).
   Google Scholar
• Kori SH, McDonald SA, Page RC et al. Gastric transit and absorption of reformulated and conventional sumatriptan tablets in migraineurs both during and outside of a migraine attack: evaluation by gastric scintigraphy. Neurology66(Suppl. 2), A375 (2006) (Abstract P06.184).
   Google Scholar
• Carpay J, Scoenen J, Ahmad F et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther.26, 214–223 (2004) .
   PubMed Web of Science ®Google Scholar
• Barbanti P, Carpay JA, Kwong WJ, Ahmad F, Boswell D. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr. Med. Res. Opin.20, 2021–2029 (2004).
   PubMed Web of Science ®Google Scholar
• Sheftell FD, Dahlöf CGH, Brandes JL et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin. Ther.27(4), 19–26 (2005).
   Google Scholar
• Agosti R, Dahlöf CGH, Mulleners WM et al. Time to onset of efficacy of the fast-disintegrating/rapid-release formulation of sumatriptan tablets in the acute treatment of migraine. Headache Care3(1), 3–10 (2006).
   Google Scholar
• Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin. Proc.78, 1214–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache38(3), 184–190 (1998).
   PubMed Web of Science ®Google Scholar
• Savani N, Loftus J, Boswell D. A randomized, double-blind, placebo-controlled, parallel group evaluation of sumatriptan 50-mg and 100-mg tablets administered during the mild pain phase of a menstrually associated migraine attack. Cephalalgia22, 606 (2002).
   Google Scholar
• Allais G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol. Sci.25(Suppl. 3), S229–S231 (2004).
   Google Scholar
• Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache46(Suppl. 2), S55–S60 (2006).
   Google Scholar
• Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs19(11), 951–972 (2005).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache45(2), 156–162 (2005).
   PubMed Web of Science ®Google Scholar
• Salonen R, Saiers J. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia19(1), 16–19 (1999).
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR. 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache38, 288–291 (1998).
   PubMed Web of Science ®Google Scholar
• Barbanti P, Fabbrini G, Vanacore N, Pesare M, Buzzi MG. Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. Headache43(4), 400–403 (2003).
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Pini LA, Zanchin G et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia26(3), 257–265 (2006).
   PubMed Web of Science ®Google Scholar
• Meckling SK, WJ, Rose MS, Dalby JT. Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients. Can. J. Neurol. Sci.28(4), 313–318 (2001).
   PubMed Web of Science ®Google Scholar
• Visser WH, de Vriend RHM, Jasper NHWM, Ferrari MD. Sumatriptan nonresponders: a survey in 366 migraine patients. Headache36, 471–475 (1996).
   PubMed Web of Science ®Google Scholar